| 9.27 0.08 (0.87%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 11.07  |
1-year : | 12.93 |
| Resists | First : | 9.47 |
Second : | 11.07 |
| Pivot price | 8.67 |
|||
| Supports | First : | 8.13 |
Second : | 7.3 |
| MAs | MA(5) : | 8.99 |
MA(20) : | 8.43 |
| MA(100) : | 8.57  |
MA(250) : | 8.21 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 83.7 |
D(3) : | 77.8 |
| RSI | RSI(14): 64 |
|||
| 52-week | High : | 11.72 | Low : | 6.05 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ VYGR ] has closed below upper band by 15.7%. Bollinger Bands are 2.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.49 - 9.51 | 9.51 - 9.55 |
| Low: | 9.1 - 9.13 | 9.13 - 9.17 |
| Close: | 9.21 - 9.26 | 9.26 - 9.32 |
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Tue, 23 Jul 2024
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Tue, 23 Jul 2024
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Tue, 23 Jul 2024
BNP Paribas Financial Markets Raises Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Sun, 21 Jul 2024
Empowered Funds LLC Purchases 2,975 Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) - Defense World
Sat, 20 Jul 2024
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives $18.00 Consensus Target Price from Brokerages - MarketBeat
Mon, 13 May 2024
Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 16.9 (%) |
| Held by Institutions | 64.6 (%) |
| Shares Short | 3,840 (K) |
| Shares Short P.Month | 4,260 (K) |
| EPS | -0.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.28 |
| Profit Margin | -2.6 % |
| Operating Margin | -83 % |
| Return on Assets (ttm) | -2.7 % |
| Return on Equity (ttm) | -1.1 % |
| Qtrly Rev. Growth | -87 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.18 |
| EBITDA (p.s.) | -0.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 13 (M) |
| Levered Free Cash Flow | 71 (M) |
| PE Ratio | -54.53 |
| PEG Ratio | 0 |
| Price to Book value | 1.47 |
| Price to Sales | 4.23 |
| Price to Cash Flow | 38.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|